Shingles vaccine study targets patients on immune drugs
NCT ID NCT07534007
First seen Apr 23, 2026 · Last updated May 11, 2026 · Updated 1 time
Summary
This study looks at how the shingles vaccine (Shingrix) works in people with psoriasis or myelofibrosis who are taking medications that affect the immune system. Researchers will compare the immune response in 150 participants—some on these therapies and some not—to see if the vaccine still provides strong protection. The goal is to understand vaccine effectiveness in these vulnerable groups.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RZV VACCINE (SHINGRIX ®) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fondazione IRCCS Policlinico San Matteo di Pavia
RECRUITINGPavia, Lombarda, 27100, Italy
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.